Kirti S Prabhu, Fareed Ahmad, Shilpa Kuttikrishnan, Rari Leo, Tayyiba Akbar Ali, Mahmoud Izadi, Jericha M Mateo, Majid Alam, Aamir Ahmad, Ammira S Al-Shabeeb Akil, Ajaz A Bhat, Joerg Buddenkotte, Ehsan Pourkarimi, Martin Steinhoff, Shahab Uddin
Non-melanoma skin cancer (NMSC), encompassing basal and squamous cell carcinoma, is the most prevalent cancer in the United States. While surgical removal remains the conventional therapy with a 95% 5-year cure rate, there is a growing interest in exploring alternative treatment strategies. In this study, we investigated the role of Bortezomib (BTZ), a proteasome inhibitor, in NMSC. Using two NMSC cell lines (A431 and A388), we examined the effects of BTZ treatment. Our results demonstrated that 48 h of BTZ treatment led to downregulating Skp2 expression in both A431 and A388 cells while upregulating p53 expression, specifically in A388 cells...
May 9, 2024: Cell Death Discovery